Allarity Therapeutics

OMX: ALLR

Market CapSEK593m

Last Close SEK1.52

Denmark-based biopharmaceutical company Allarity Therapeutics’ patent-protected mRNA-based DRP platform enables the identification of patients with gene expression highly likely to respond to treatment. It is advancing the PARP inhibitor stenoparib (2X-121), the TKI dovitinib and microtubule inhibitor Ixempra.

More Allarity Therapeutics content >

Investment summary

Allarity Therapeutics holds the worldwide drug development rights to the drug response predictor (DRP), a microarray technology that examines the expression of a panel of genes to discover potential responders to cancer therapies. Lead assets include: tyrosine kinase inhibitor (TKI) dovitinib, poly-ADP-ribose polymerase (PARP) inhibitor stenoparib, and microtubule inhibitor agent Ixempra. In Q3 CY21 the company’s PMA for the dovitinib companion diagnostic agent was accepted by the FDA. The company plans to file an NDA for dovitinib for the treatment of renal cell carcinoma in 2021.

Y/E Dec
Revenue (DKKm)
EBITDA (DKKm)
PBT (DKKm)
EPS (ore)
P/E (x)
P/CF (x)
2019A 0.8 (66.5) (174.9) (208.11) N/A N/A
2020A 0.0 (59.0) (59.1) (29.22) N/A N/A
2021E 0.0 (69.9) (70.9) (30.59) N/A N/A
2022A 0.0 (247.2) (248.2) (97.04) N/A N/A
Industry outlook

Allarity and the DRP system have the potential to identify the value in drug assets that have otherwise been discontinued by identifying patient populations where these drugs are active. The company as a portfolio of six product candidates. This allows the company to in-license these assets at low cost; it may then out-license them after clinical validation.

Last updated on 21/09/2021
Content on Allarity Therapeutics
Allarity Therapeutics – Coming to Nasdaq
Healthcare | Update | 8 June 2021
pipettes_
View more
Register to receive research on Allarity Therapeutics as it is published
Share price graph
Balance sheet
Forecast net debt (DKKm) 97.5
Forecast gearing ratio (%) 137
Price performance
%
1m
3m
12m
Actual (33.5) 61.7 1.5
Relative* (30.2) 56.5 (24.4)
52-week high/low SEK2.4/SEK0.6
*% relative to local index
Key management
Duncan Moore Chairman
Steve Carchedi CEO
Jens Erik Knudsen CFO